| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5692566 | European Urology | 2016 | 5 Pages |
Abstract
Taxanes are the most active chemotherapy agents in metastatic resistant prostate cancer. However, not all patients respond to this therapy. In the present study we show that the detection of TMPRSS2-ERG in blood from metastatic resistant prostate cancer patients predicts resistance to docetaxel and it may be useful to select treatment and to avoid possible toxicities in refractory patients.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Ãscar Reig, Mercedes MarÃn-Aguilera, Gemma Carrera, Natalia Jiménez, Laia Paré, Susana GarcÃa-Recio, Lydia Gaba, Maria Verónica Pereira, Pedro Fernández, Aleix Prat, Begoña Mellado,